Industry & Policy News

[Vascular Perfusion Solutions (Globe Newswire)] The partnership between Vascular Perfusion Solutions and Unravel Biosciences, Inc. utilizes Unravel’s target and drug discovery platform, BioNAV™, which leverages a gene expression network AI model of human health to advance drugs for complex diseases in a target-agnostic manner, to identify small molecule modulators of endothelial activation.

[University of Bonn] Another big success for the University of Bonn in securing grants from the European Research Council (ERC), with three researchers receiving an ERC Consolidator Grant: Drs. Jan Hasenauer, Florian I. Schmidt, and Evgeny Shinder.

[Stat] The World Health Organization and Chinese health officials convened via a conference call as the global health agency sought information about reports of increases in respiratory illnesses among children in China that have put disease watchers elsewhere on alert.

[Hepion Pharmaceuticals, Inc.] Hepion Pharmaceuticals, Inc. announced additional efficacy data for rencofilstat, its lead drug candidate for the treatment of metabolic dysfunction-associated steatohepatitis, fibrotic diseases, HCC, and other chronic diseases.

[Science] Artificial intelligence tools promise to help researchers digest scholarly literature in new ways, but technical and legal barriers may hinder widespread use.

[BioStem Technologies, Inc.] BioStem Technologies Inc. announced that the Centers for Medicare and Medicaid Services has published a new Q code for VENDAJE AC® pursuant to its application for Healthcare Common Procedure Coding System “Q” codes. VENDAJE AC is a human connective tissue matrix comprised of dehydrated amniotic/chorionic tissue processed using BioStem’s proprietary BioREtain® process.